Brokerages Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Price Target at $13.36

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have been assigned a consensus rating of “Moderate Buy” from the fourteen brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $13.3636.

A number of equities research analysts have recently issued reports on the stock. Leerink Partners upgraded shares of Compass Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 26th. D. Boral Capital reissued a “buy” rating and issued a $30.00 price objective on shares of Compass Therapeutics in a report on Tuesday, January 6th. Canaccord Genuity Group set a $13.00 price objective on Compass Therapeutics in a research note on Wednesday, February 4th. Cantor Fitzgerald started coverage on Compass Therapeutics in a research report on Wednesday, December 3rd. They issued an “overweight” rating for the company. Finally, Raymond James Financial reissued an “outperform” rating and set a $9.00 price target on shares of Compass Therapeutics in a research report on Tuesday, January 6th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Russell Investments Group Ltd. grew its position in shares of Compass Therapeutics by 3,933.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after buying an additional 7,592 shares during the last quarter. Creative Planning acquired a new position in Compass Therapeutics in the second quarter valued at approximately $30,000. Flagship Harbor Advisors LLC bought a new position in shares of Compass Therapeutics during the fourth quarter valued at approximately $32,000. Strs Ohio bought a new position in shares of Compass Therapeutics during the first quarter valued at approximately $34,000. Finally, Apollon Wealth Management LLC acquired a new stake in shares of Compass Therapeutics during the 3rd quarter worth approximately $35,000. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Trading Down 4.5%

Shares of NASDAQ:CMPX opened at $5.89 on Friday. The firm has a market cap of $1.05 billion, a PE ratio of -13.09 and a beta of 1.46. The company has a fifty day simple moving average of $5.79 and a 200 day simple moving average of $4.65. Compass Therapeutics has a 12-month low of $1.33 and a 12-month high of $6.88.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.